Catalyst OrthoScience Secures $15M for Shoulder Arthroplasty Advancement
October 24, 2025, 3:40 am
Catalyst OrthoScience, a Naples-based medical technology firm, closed a $15 million equity and debt financing round. The investment strengthens its balance sheet and accelerates high-growth commercial and clinical programs. RC Capital led the funding, with support from Mutual Capital Partners, Dr. Derace Schaffer, and Western Alliance Bank. Catalyst advances shoulder arthroplasty through innovative, surgeon-centric systems. This capital infusion expands its U.S. market footprint in hospitals and ASCs. The company also appointed Dr. Theodore Blaine to its board, adding crucial orthopedic expertise. This move underscores Catalyst's commitment to transforming shoulder replacement for better patient outcomes and surgical efficiency.
Catalyst OrthoScience, a leading medical technology innovator, has secured a substantial $15 million in new financing. This equity and debt funding round marks a pivotal moment. It strengthens the company's position in the competitive orthopedic market. The investment targets accelerated growth across key initiatives.
The funding was spearheaded by RC Capital. Mutual Capital Partners, Dr. Derace Schaffer, and Western Alliance Bank also participated. This coalition of investors signals strong confidence in Catalyst's strategic direction. The capital infusion occurred on October 22, 2025. It positions Catalyst for significant expansion.
Company leaders will deploy these funds strategically. The primary goals include fortifying the balance sheet. They also plan to advance high-growth commercial programs. Clinical programs will see increased support. This holistic approach ensures robust, sustained development. It propels Catalyst's innovative solutions forward.
Catalyst OrthoScience, based in Naples, Florida, was founded in 2014. Orthopedic surgeon Dr. Steven Goldberg established the company. Its core mission focuses on redefining shoulder arthroplasty. This involves simplified, surgeon-focused innovation. The company's systems are engineered for both precision and efficiency in shoulder replacement surgery.
The company offers a portfolio of advanced shoulder replacement systems. This includes the recently launched Catalyst Fracture Shoulder System. These systems are gaining significant traction among surgeons. They value the streamlined design. They also appreciate the focus on improving patient outcomes. Surgical procedures become simpler, not more complex.
Catalyst's technology is built on a foundation of innovation. Its solutions aim to preserve bone and soft tissue. They also work to reduce complications. Ultimately, they restore natural movement. This patient-centric approach underpins the company's research and development. It defines its product offerings.
The new financing will accelerate the adoption of Catalyst's technology. It will expand the company's U.S. footprint. The presence across hospitals continues to grow. Ambulatory Surgery Centers (ASCs) are also a key target market. This expansion reinforces Catalyst's market leadership in orthopedic surgery.
A significant development accompanies this funding round. Dr. Theodore Blaine has been appointed to the company's board of directors. Dr. Blaine is a renowned orthopedic shoulder surgeon at the Hospital for Special Surgery (HSS). He brings deep clinical expertise to the board. His commitment to evidence-based medical innovation aligns perfectly with Catalyst's ethos.
Dr. Derace Schaffer, an existing Catalyst board member, also reaffirmed his strong confidence. He is a physician and entrepreneur. His long-standing involvement highlights the stability of Catalyst's governance. He possesses extensive experience guiding healthcare ventures. His conviction further validates the company's trajectory.
Catalyst OrthoScience holds a strong portfolio of issued and pending patents. This intellectual property protects its innovative shoulder arthroplasty solutions. The technology is already available across the entire U.S. market. This widespread availability supports continued growth and surgeon adoption.
The company's vision extends beyond individual product sales. It aims to advance orthopedic surgery broadly. Its innovation prioritizes both patient outcomes and surgical efficiency. This dual focus defines Catalyst's approach to healthcare technology. It creates value for patients, surgeons, and the healthcare system.
Growing surgeon base and expanding presence define Catalyst's operational success. Increasing investor confidence underscores its financial health. The company executes its mission with discipline. It simplifies complex orthopedic procedures. It never compromises on quality or results.
This $15 million capital infusion represents a major vote of confidence. It empowers Catalyst OrthoScience to further its mission. The company will continue to innovate in shoulder arthroplasty. It will expand market reach. It will ultimately improve patient lives through advanced, surgeon-centric medical technology. This funding propels Catalyst into a new era of growth and impact.
Catalyst OrthoScience, a leading medical technology innovator, has secured a substantial $15 million in new financing. This equity and debt funding round marks a pivotal moment. It strengthens the company's position in the competitive orthopedic market. The investment targets accelerated growth across key initiatives.
The funding was spearheaded by RC Capital. Mutual Capital Partners, Dr. Derace Schaffer, and Western Alliance Bank also participated. This coalition of investors signals strong confidence in Catalyst's strategic direction. The capital infusion occurred on October 22, 2025. It positions Catalyst for significant expansion.
Company leaders will deploy these funds strategically. The primary goals include fortifying the balance sheet. They also plan to advance high-growth commercial programs. Clinical programs will see increased support. This holistic approach ensures robust, sustained development. It propels Catalyst's innovative solutions forward.
Catalyst OrthoScience, based in Naples, Florida, was founded in 2014. Orthopedic surgeon Dr. Steven Goldberg established the company. Its core mission focuses on redefining shoulder arthroplasty. This involves simplified, surgeon-focused innovation. The company's systems are engineered for both precision and efficiency in shoulder replacement surgery.
The company offers a portfolio of advanced shoulder replacement systems. This includes the recently launched Catalyst Fracture Shoulder System. These systems are gaining significant traction among surgeons. They value the streamlined design. They also appreciate the focus on improving patient outcomes. Surgical procedures become simpler, not more complex.
Catalyst's technology is built on a foundation of innovation. Its solutions aim to preserve bone and soft tissue. They also work to reduce complications. Ultimately, they restore natural movement. This patient-centric approach underpins the company's research and development. It defines its product offerings.
The new financing will accelerate the adoption of Catalyst's technology. It will expand the company's U.S. footprint. The presence across hospitals continues to grow. Ambulatory Surgery Centers (ASCs) are also a key target market. This expansion reinforces Catalyst's market leadership in orthopedic surgery.
A significant development accompanies this funding round. Dr. Theodore Blaine has been appointed to the company's board of directors. Dr. Blaine is a renowned orthopedic shoulder surgeon at the Hospital for Special Surgery (HSS). He brings deep clinical expertise to the board. His commitment to evidence-based medical innovation aligns perfectly with Catalyst's ethos.
Dr. Derace Schaffer, an existing Catalyst board member, also reaffirmed his strong confidence. He is a physician and entrepreneur. His long-standing involvement highlights the stability of Catalyst's governance. He possesses extensive experience guiding healthcare ventures. His conviction further validates the company's trajectory.
Catalyst OrthoScience holds a strong portfolio of issued and pending patents. This intellectual property protects its innovative shoulder arthroplasty solutions. The technology is already available across the entire U.S. market. This widespread availability supports continued growth and surgeon adoption.
The company's vision extends beyond individual product sales. It aims to advance orthopedic surgery broadly. Its innovation prioritizes both patient outcomes and surgical efficiency. This dual focus defines Catalyst's approach to healthcare technology. It creates value for patients, surgeons, and the healthcare system.
Growing surgeon base and expanding presence define Catalyst's operational success. Increasing investor confidence underscores its financial health. The company executes its mission with discipline. It simplifies complex orthopedic procedures. It never compromises on quality or results.
This $15 million capital infusion represents a major vote of confidence. It empowers Catalyst OrthoScience to further its mission. The company will continue to innovate in shoulder arthroplasty. It will expand market reach. It will ultimately improve patient lives through advanced, surgeon-centric medical technology. This funding propels Catalyst into a new era of growth and impact.